{
    "clinical_study": {
        "@rank": "139583", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab and Pemetrexed/cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d"
            }, 
            {
                "arm_group_label": "Pemetrexed/cisplatin", 
                "arm_group_type": "Active Comparator", 
                "description": "Pemetrexed/cisplatin q21d"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center phase II randomized controlled study to assess the efficacy of\n      Pemetrexed/cisplatin with or without Bevacizumab on patients with brain metastasis from\n      non-small cell lung cancer(NSCLC) harboring EGFR wild type by intracranial PFS(iPFS),also\n      PFS ,DCR and OS.The side effect is evaluated as well."
        }, 
        "brief_title": "Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non Squamous Non-small Cell Lung Cancer", 
            "Brain Metastases", 
            "Bevacizumab"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient who was confirmed stage IV non squamous NSCLC with EGFR wild type and brain\n             metastases by pathologic histology or cytology\n\n          2. Patients who had never received therapy (including chemotherapy,WBRT,and Bevacizumab)\n             after diagnosed brain metastases\n\n          3. Appraisable disease, the presence of at least three lesions if longest diameter <10\n             mm by brain MRI\n\n          4. Adult patients (\u2265 18 years and \u226475 years). ECOG Performance Status 0 or 1 Life\n             expectancy of at least 12 weeks.,Haemoglobin \u00b3 10.0 g/dl, Absolute neutrophil count\n             (ANC) \u00b31.5 x 109/L, platelets \u00b3 100 x 109/L. Total bilirubin \u00a3 1.5 x upper limit of\n             normal (ULN). ALT and AST < 2.5 x ULN in the absence of liver metastases, or < 5 x\n             ULN in case of liver metastases. Creatinine clearance \u00b3 60ml/min (calculated\n             according to Cockcroft-gault formula).\n\n          5. Patients should be contraceptive during the period of the trial\n\n        Exclusion Criteria:\n\n          1. Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a\n             predominant squamous component.\n\n          2. History of haemoptysis\n\n          3. Evidence of tumour invading major blood vessels on imaging.\n\n          4. Patient was received irradiation of brain. Patient with meningeal metastases were\n             confirmed by MRI or cytology test of cerebrospinal fluid.\n\n          5. Previous radiotherapy.\n\n          6. Serious uncontrolled coagulation disorder or thrombi-embolic complications within 6\n             months prior to study start or history of serious bleeding complications.\n\n          7. Major surgical procedures within 4 weeks prior to study entry.\n\n          8. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior\n             to the first bevacizumab infusion.\n\n          9. Non-healing wound, active peptic ulcer or bone fracture.\n\n         10. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess\n             within 6 months of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951482", 
            "org_study_id": "NSCLC brain metastasis 02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pemetrexed/cisplatin", 
                "description": "receive Pemetrexed/cisplatin every 21 days", 
                "intervention_name": "Pemetrexed/cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bevacizumab and Pemetrexed/cisplatin", 
                "description": "receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days", 
                "intervention_name": "Bevacizumab and Pemetrexed/cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Bevacizumab", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 10, 2013", 
        "location": {
            "contact": {
                "email": "chenlk@sysucc.org.cn", 
                "last_name": "li-kun Chen, doctor", 
                "phone": "13798019964"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University of Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type", 
        "other_outcome": [
            {
                "measure": "PFS: progress free survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "OS: overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "overall_contact": {
            "last_name": "li-kun hen, Doctor", 
            "phone": "13798019964"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "li-kun Chen, Doctor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compare iPFS(intracranial progression free survival) in two arms", 
            "safety_issue": "Yes", 
            "time_frame": "3 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951482"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Li-kun Chen", 
            "investigator_title": "medical doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Response rate(CR&PR)", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}